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mechanical trauma. In contrast to the
previous report, in which the clinico-
pathologic features were not diagnostic
for any particular subtype of epidermoly-
sis bullosa (McGrath et al., 2012), our
morphological findings allowed a
definite classification as autosomal
recessive EBS.
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TO THE EDITOR
Hereditary epidermolysis bullosa (EB)
comprises a genetically and clinically
heterogeneous group of disorders char-
acterized by trauma-induced skin blis-
tering (Fine et al., 2008). EB can be
caused by mutations in more than 15
different genes and is classified into four
main types according to the level of skin
cleavage: EB simplex, junctional EB,
dystrophic EB, and Kindler syndrome
(Fine et al., 2008; Bruckner-Tuderman
and Has, 2012). Well-defined severe sub-
types are associated with typical clinical
features and molecular pathology. In
contrast, skin biopsies from patients with
mild skin fragility often do not exhibit
either skin cleavage or abnormalities of
dermal–epidermal junction proteins,
which hampers determination of the EB
subtype or the candidate gene. In such
cases, the precise diagnosis may be
difficult and delayed. These phenotypes
are associated with missense or splice-site
mutations in genes coding for proteins
that interact closely in dermal–epidermal
adhesion networks (Bruckner-Tuderman
and Has, 2012).
Here, we report on 15 patients with a
distinct phenotype comprising late-onset
skin blistering, progressive skin atrophy,
loss of dermatoglyphs, scarring, and nail
anomalies, accompanied by irregular
deposition of basement membrane–
associated proteins.
See related commentary on pg 602
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Abbreviations: COL, collagenous domain; COL17A1, collagen XVII gene; EB, epidermolysis bullosa;
FERMT1, kindlin-1 gene; NC, non-collagenous domain
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Clinical features of the patients are
summarized in the Supplementary
Table S1 online. Patients 1 and 2 pre-
sented with skin blistering, leading to
scarring and pronounced skin atrophy.
Nails were either lost or dystrophic
(Figure 1a). Both patients originated from
one large consanguineous kindred and
had four similarly affected relatives.
Patient 3 was referred for mild acral skin
blistering, which started at the age of 6
years and resolved with mild atrophic
scarring. Some finger nails were lost,
whereas all toe nails were either lost or
dystrophic (Figure 1b). The younger sib-
ling (patient 4) was similarly affected but
occasionally had oral blisters. Patient 5
had skin blistering and pronounced skin
atrophy, loss of dermatoglyphs, and loss
of nails (Supplementary Figure S1 online).
The clinical features of patient 6 included
the onset of skin blistering at the age of 10
years, skin atrophy, sclerosis and contrac-
tures of fingers, loss of dermatoglyphs,
and diffuse palmoplantar keratoderma.
In patients 1–6, immunofluorescence
microscopy was performed, as des-
cribed previously, to determine the
EB subtype (Almaani et al., 2009;
Kiritsi et al., 2011). This revealed no
skin cleavage, with all proteins of the
dermal–epidermal junction zone present
at similar intensities to controls. How-
ever, the pattern of labeling was abnor-
mal with extensive immunostaining for
collagens XVII, IV, and VII throughout the
papillary dermis (Figure 1c). Transmission
electron microscopy revealed no clear
plane of tissue fragility in patients 1 and
6; there were focal basement-membrane
interruptions and extensive reduplication
of the lamina densa, as well as deposition
of amorphous material in the superficial
dermis (Figure 1d). On the basis of the
immunofluorescence staining pattern of
collagen XVII, VII, and IV, we predict that
this material corresponds to these base-
ment-membrane proteins, irregularly
distributed in the papillary dermis.
Both clinical and skin morphological
features strongly suggested the diagnosis
of Kindler syndrome (Supplementary
Figure S1 online and Supplementary
Table S2 online), which is characterized
by mild skin blistering and progressive
skin atrophy, and is caused by muta-
tions in the kindlin-1 gene (FERMT1).
The project was approved by the ethics
committee of the University of Freiburg
and was conducted according to the
Declaration of Helsinki Principles. After
obtaining written informed consent,
FERMT1 mutation analysis was perfor-
med in patients 1, 3, 5, and 6, as des-
cribed (Lai-Cheong and McGrath, 2010;
Has et al., 2011), but no pathogenic
variants were identified. In patient 1,
mutations in the collagen VII gene
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Figure 1. Clinical and skin morphological features of the patients with the COL17A1 mutation
c.3908G4A, p.R1303Q. (a) Patient 1 had skin blistering on the lower legs, resolving with scarring,
atrophy, and dyspigmentation, and skin atrophy, most prominent over the dorsal aspects of hands and feet.
(b) Partial loss of finger and toenails in patient 3. (c) Immunofluorescence staining patterns with antibodies
to collagens XVII (mAb-123, gift of P. Marinkovich, Stanford, USA), IV (COL94, Sigma-Aldrich, Poole, UK),
and VII (LH7.2, Sigma-Aldrich) (green) in a control and patient 1 demonstrate an irregular, increased
deposition of all markers in the papillary dermis of the patient, in contrast to the normal linear pattern.
Nuclei are stained with 40,6-diamidino-2-phenylindole. (d) Transmission electron microscopy images of
skin samples of a control and patient 1 are shown. It demonstrates the loss of hemidesmosomes, loss of
lamina lucida, obscure anchoring fibers because of amorphous material immediately below the basal cell
membrane in the patient. Amorphous material is also present in the papillary dermis (arrows). Insets
represent twofold magnifications of the marked areas.
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(COL7A1) were excluded as a cause of
dystrophic EB and, subsequently, exome
sequencing (McGrath et al., 2012)
revealed the mutation c.3908G4A,
p.R1303Q in the gene for collagen XVII,
COL17A1, in a homozygous state. This
was confirmed by Sanger sequencing
as described previously (Almaani et al.,
2009; Kiritsi et al., 2011) and led us to the
disclosure of the same homozygous
mutation in patients 2–6. Further, on the
basis of genotype–phenotype correlation,
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Figure 2. Consequences of the collagen XVII gene mutation, c.3908G4A, p.R1303Q. (a) Schematic representation of the collagen XVII molecule with the
intracellular endodomain, and the extracellular ectodomain. The collagenous (COL, yellow) and non-collagenous (NC, gray) domains and the position of the
amino-acid substitution p.R1303Q (red R4Q) are depicted, as well as epitopes of the domain-specific antibodies used in this study. In the lower panel, the
sequence stretch flanking the mutation site spanning amino acids 1215–1398 is shown in detail. Secondary protein structure prediction revealed profound
structural modifications in mutant collagen XVII upstream and downstream of the mutation site (indicated by asterisks). (b) Immunofluorescence staining was
performed with the following domain-specific antibodies to collagen XVII: Endo2, NC16A, and Hk139 (Nishie et al., 2010), and skin sections from a healthy
control, patients 3 and 8, and a patient with junctional EB-other (JEB-o) and loss-of-function mutations leading to absence of collagen XVII. Note apicolateral
staining in the basal keratinocytes with the antibody Endo2 in patients 3 and 8, similar to the control skin. Immunostaining patterns with Hk139 and NC16A, which
recognize the ectodomain of collagen XVII, demonstrated a broad, irregular distribution below the level of the basement membrane in intact skin of the patients 3
(P3) and 8 (P8) and the presence of the signal at both roof and base of a blister in patient 8. (c) Immunofluorescence staining with an antibody to the laminin
g2 chain (clone GB3) shows broad, irregular distribution below the level of the basement membrane in the intact skin of patient 3. Laminin g2 immunostaining is
present at both roof and floor of the blister in patient 8 and only at the blister floor in a patient with junctional EB-other with COL17A1 loss-of-function
mutations. (d) Immunofluorescence staining with an antibody for tenascin C (clone 578, R&D Systems) shows a low expression in control skin but very abundant
deposition in the skin of patients 3 and 8. Bars¼50mm, asterisks indicate blisters, and nuclei are stained with 40,6-diamidino-2-phenylindole. EB, epidermolysis
bullosa.
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we identified patients 7–15 to be homo-
zygous or compound heterozygous for
the COL17A1 mutation c.3908G4A,
p.R1303Q (Supplementary Table S1
online). Although all patients (1–15)
had similar clinical features, mucosal
involvement seemed to be variable and
was more pronounced in patients 8
and 9, who had microstomia, esophageal
stenosis, corneal erosions, ectropion,
and lacrimal duct obstruction. Scarring
leading to scleroderma-like fingers and
contractures of the hands developed
with age (Supplementary Figure S2
online). In patients 2, 8, 9, and 11–14,
enamel pitting and/or carious teeth
were reported. Beyond androgenetic
type of alopecia in patients 8 and 9,
no hair abnormality was noted.
Collagen XVII, a type II–oriented
transmembrane protein, is a hemi-
desmosomal component with multiple
intracellular and extracellular binding
partners, e.g., BP230, integrin a6b4,
and laminin-332 (Has and Kern, 2010).
Each collagen XVII molecule is a
homotrimer of three 180 kDa a1(XVII)
chains with an N-terminal endodomain,
a short transmembrane stretch, and a
C-terminal ectodomain composed of 15
collagenous subdomains, interrupted by
16 non-collagenous sequences (Franzke
et al., 2005). Most mutations abrogate
or significantly reduce collagen XVII
expression, whereas glycine substi-
tutions in the collagenous domains
decrease thermal stability (Vaisanen
et al., 2005), or cause intracellular accu-
mulation of collagen XVII and affect its
posttranslational modifications (Huilaja
et al., 2009). The mutation p.R1303Q is
located in the fourth non-collagenous
domain of the a1(XVII) chain, which is a
part of the putative laminin-332 binding
region in collagen XVII (Tasanen et al.,
2004). Secondary protein structure ana-
lysis of the a1(XVII) chain containing the
amino-acid substitution p.R1303Q was
performed with SSpro v4.5 software
(Cheng et al., 2005), and predicted pro-
nounced changes in the structural
integrity within this binding region
(Figure 2a), suggesting that those modi-
fications result in abnormal laminin-332
binding. Importantly, collagen XVII
expression was preserved in patients
with homozygous p.R1303Q, as detec-
ted with antibodies to both the intra-
cellular and the extracellular domains
(Figure 2b). This was sufficient for a
relative mechanical stability of the skin,
as no cleavage was noted in most of the
skin sections. Nevertheless, if junctional
skin cleavage was noted, collagen XVII
and the laminin g2 chains were present
both at the roof and the floor of the
blister (Figure 2b and c). These findings
suggest abnormal, covalent interactions
of the mutant collagen XVII with lami-
nin-332. Presumably, the new gluta-
mine at position 1303 that is generated
by the mutation may serve as a novel
transamidation site for tissue transgluta-
minase (Schumann et al., 1997), which
consequently crosslinks collagen XVII
and laminin-332 and disorganizes
the supramolecular basement-membrane
networks at the dermal–epidermal junc-
tion (Behrens et al., 2012). In line with
this hypothesis, a transglutaminase
activity assay (Franzke et al., 2012)
suggested relatively high activity levels
(pH 8.4) at the dermal–epidermal junc-
tion in the skin of patient 3, compared
with three control skin samples (Supple-
mentary Figure S3 online). As a marker
for tissue remodeling, tenascin C was
abundantly deposited below the base-
ment-membrane zone in the papillary
dermis in patients 3 and 8 (Figure 2d).
The irregular, broad staining pattern
of collagen XVII, IV, and VII, laminin g2
chain, and tenascin C as well as the
significant interruptions and duplications
of the lamina densa were reminiscent of
the Kindler syndrome (Has et al., 2011).
These particular morphological features
associated with p.R1303Q are less
evident in compound heterozygous
status with null mutations (not shown).
Although several individuals with the
mutation p.R1303Q have been reported
in the literature (Schumann et al., 1997;
Kiritsi et al., 2011; Yuen et al., 2011),
the present cohort including 15 patients
allows the definition of the distinct
molecular and phenotypic features
caused by this amino-acid substitution.
Similar immunofluorescence and ultra-
structural features were already described
by Yuen et al. (2011). The mutation
p.R1303Q affects the structure of colla-
gen XVII and its molecular interactions
and determines late-onset junctional
EB, which is distinct from junctional
EB-other (also known as non-Herlitz)
with COL17A1 loss-of-function mutations
but resembles in many aspects Kindler
syndrome (Supplementary Figure S1
online and Supplementary Table S2
online). The features that allow the dis-
tinction between these two entities
include nail loss, lack of photosensitivity,
and the presence of electron-dense amor-
phous material in the upper dermis in
junctional EB due to the amino-acid
substitution p.R1303Q in collagen XVII.
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TO THE EDITOR
In genetic counseling of autosomal rece-
ssive diseases, parents of patients are
normally informed on the basis of the
Mendelian principle that both parents
are asymptomatic heterozygous carriers
and the risk of recurrence is 25% in
subsequent pregnancies (Fassihi et al.,
2006). However, there are several exce-
ptions, including cases with uniparental
disomy (UPD). UPD is a condition in
which a pair of chromosomes are
inherited from only one parent
(Zlotogora, 2004). There are two types
of UPD, uniparental isodisomy and
uniparental heterodisomy (Zlotogora,
2004). When one chromosome is
present in duplicate, the situation is
described as isodisomy. When both
chromosomes from one parent are
present, the situation is heterodisomy
(Kotzot, 2001; Siegel and Slavotinek,
2005). Thus, homozygosity for a
recessive mutation may result from uni-
parental isodisomy. This study reports a
case of Netherton syndrome (NS, MIM
256500), an autosomal recessive
syndromic type of ichthyosis, showing
complete maternal isodisomy of chro-
mosome 5 with a pathogenic mutation
in serine protease inhibitor Kazal-type 5
(SPINK5; Bitoun et al., 2002; Sun and
Linden, 2006).
The patient was a 10-year-old Japa-
nese girl, whose clinical and histopatho-
logical details have been described
recently (Akagi et al., 2013). In brief,
she demonstrated typical symptoms of
NS, including ichthyosiform erythro-
derma, bamboo hairs, and atopic
features (Figure 1a and b). She showed
moderate disease severity without any
additional extracutaneous abnormalities.
See Supplementary Data for further clin-
ical information.
All described studies were performed
following the guidelines of the medical
ethical committee of Kurume University
School of Medicine. Written informed
consent was obtained from each indivi-
dual, and the study was conducted
according to the Declaration of Helsinki
Principles.
Direct nucleotide sequencing of exon
19 of SPINK5 for the patient’s genomic
DNA disclosed a recurrent homozygous
mutation p.Arg578X (Figure 1c). How-
ever, although the mother was a hetero-
zygous carrier of this mutation, theAccepted article preview online 16 September 2013; published online 17 October 2013
Abbreviations: CP, crossing point; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, Netherton
syndrome; SPINK5, serine protease inhibitor Kazal-type 5; UPD, uniparental disomy
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